Flerie AB’s (publ) portfolio company Mendus has enrolled the first patient in the VITAL-CML trial, a phase 1b trial evaluating Mendus’ lead product vididencel in patients with chronic myeloid leukemia (CML).
The VITAL-CML trial is a phase 1b trial enrolling up to 24 patients. Topline safety and early molecular response data from the first 8 patients are expected in the second half of 2026. Positive results will trigger the VITAL-TFR2 phase 2a trial, which will assess whether vididencel can improve rates of treatment-free remission (TFR) among patients who have previously failed to achieve it.
“Mendus' immunotherapies have the potential to improve long-term survival and quality of life for cancer patients, and we are encouraged to see the clinical development progressing with patients now enrolling across multiple trials. Mendus exemplifies the kind of high-impact, science-driven company we are committed to supporting where medical need remains significant,” says Arvid Söderhäll, Venture Partner at Flerie.
Read Mendus’ full press release here: https://mendus.com/news/mendus-announces-first-patient-enrolled-in-the-vital-cml-trial/
Flerie’s ownership in Mendus amounts to 23%.
For more information:
Arvid Söderhäll, Venture Partner
Email: ir@flerie.com
About chronic myeloid leukemia
Chronic myeloid leukemia (CML) is a blood cancer affecting hematopoietic stem cells. Current standard treatment with tyrosine kinase inhibitors (TKIs) is effective and overall survival is comparable to the general population, but there remains a significant unmet need for treatments that achieve treatment-free remission (TFR). An estimated 300,000 people live with CML in Europe and the US alone, with approximately 5 million affected globally and prevalence projected to reach as many as 10 million.
Flerie in brief
Flerie is an active long-term life science investor, with a broad and diversified portfolio of innovative companies based on pioneering science. We invest in product development and commercial growth opportunities globally alongside other leading investors, focusing predominantly on private companies that are otherwise difficult to access. Flerie’s active ownership model, broad network and resources support and accelerate the development of the portfolio projects, creating value for shareholders. Flerie AB’s ordinary share is listed on Nasdaq Stockholm with the ticker FLERIE. For further information please visit www.flerie.com